Celgene Corporation and its subsidiaries (collectively “we” or “our”) is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID^®, THALOMID^® and VIDAZA^® . REVLIMID^® is an oral immunomodulatory drug marketed in the U.S. and Europe for patients with multiple myeloma who have receiv... More >>

Recent News

Date Title   09/03/10 Celgene Officially Notified of ANDA Filing for REVLIMID(R) SUMMIT, N.J., Sep 03, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization to manufacture and market generic versions of REVLIMID(R) (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States. Celgene intends to vigorous...  08/26/10 Celgene Corporation Announces Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer SUMMIT, N.J., Aug 26, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) todayannounced the appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer, effective September 27, 2010. Ms. Fouse will be responsible for all finance operations at Celgene and will report to Robert J. Hugin, Chief Executive Officer of Celgene Corporation. Fouse succeeds David W. Gryska, who served as Senior Vice President and Chief Finan...  08/25/10 Celgene Expects to Receive a Paragraph IV Notification of an ANDA Filing for REVLIMID(R) SUMMIT, N.J., Aug 25, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer. Celgene intend...  08/20/10 REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan BOUDRY, Switzerland, Aug 20, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients...

More >>

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Celgene Corp. posts new information to the site. Just enter your e-mail address and click Submit.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.